B

Biolight Life Sciences Ltd
TASE:BOLT

Watchlist Manager
Biolight Life Sciences Ltd
TASE:BOLT
Watchlist
Price: 625 ILS 1.41% Market Closed
Market Cap: 27.4m ILS
Have any thoughts about
Biolight Life Sciences Ltd?
Write Note

Net Margin
Biolight Life Sciences Ltd

-3 109.6%
Current
-5 119%
Average
0%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3 109.6%
=
Net Income
-6.2m
/
Revenue
198k

Net Margin Across Competitors

Country IL
Market Cap 27.4m ILS
Net Margin
-3 110%
Country US
Market Cap 1.3T USD
Net Margin
9%
Country US
Market Cap 201.7B USD
Net Margin
14%
Country US
Market Cap 173.6B USD
Net Margin
18%
Country KR
Market Cap 67.8T KRW
Net Margin
24%
Country CH
Market Cap 38.6B CHF
Net Margin
9%
Country US
Market Cap 39.6B USD
Net Margin
22%
Country US
Market Cap 36.8B USD
Net Margin
9%
Country US
Market Cap 26.9B USD
Net Margin
21%
Country US
Market Cap 23.5B USD
Net Margin
17%
Country US
Market Cap 23.2B USD
Net Margin
21%
No Stocks Found

Biolight Life Sciences Ltd
Glance View

Market Cap
27.4m ILS
Industry
Life Sciences Tools & Services

BioLight Life Sciences Ltd. engages in the management, research and development, investments or sale of solutions, the purpose of which is to address a real need that exists in the field of eye diseases. Its portfolio companies are IOptima Novel Glaucoma Treatment and Micromedic Technologies Ltd. The firm provides each of the subsidiaries with ongoing support, resources and expertise in science, regulation, business development, and intellectual property. IOptima Novel Glaucoma Treatment is engaged in the development, manufacturing and distribution of novel surgical treatments for glaucoma. Micromedic Technologies Ltd focuses, through its investee companies, on the development and commercialization of novel molecular biomarkers related to cancer, including early detection of disease, genetic risk and optimization of treatment modalities.

BOLT Intrinsic Value
27.24 ILS
Overvaluation 96%
Intrinsic Value
Price
B

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3 109.6%
=
Net Income
-6.2m
/
Revenue
198k
What is the Net Margin of Biolight Life Sciences Ltd?

Based on Biolight Life Sciences Ltd's most recent financial statements, the company has Net Margin of -3 109.6%.